A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2004
12/14/2004	US6831171 Nucleic acid catalysts with endonuclease activity
12/14/2004	US6831106 Vitamin D analogues
12/14/2004	US6831105 For therapy and prophylaxis of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders
12/14/2004	US6831103 Composition comprising theanine
12/14/2004	US6831102 For treating or delaying progression or onset of obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, non-toxic goiter, reduced bone mass, density or growth, eating disorders, cardiac arrhythmia
12/14/2004	US6831101 Compounds that bind to one or more RANTES receptors for treatment of chemokine mediated disease states
12/14/2004	US6831097 2,3-diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
12/14/2004	US6831096 Effective against both A and B forms of influenza; oral bioavailability
12/14/2004	US6831094 For therapy of central nervous system disorders such as anxiety, depression, motor disorders
12/14/2004	US6831093 Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
12/14/2004	US6831091 Anticancer agents
12/14/2004	US6831090 Having microtubule-stabilizing effects and cytotoxic activity against rapidly proliferating cells, such as, tunior cells or other hyperproliferative cellular disease
12/14/2004	US6831089 1,4-di-substituted piperidines, some of which have M2 selectivity even higher than that of 3-alpha-chloroimperialine for treating cognitive disorders such as Alzheimer's disease
12/14/2004	US6831087 2-(Pyrid-2- or 4-yl)-1,2,3,4-tetrahydroisoquinoline and derivatives; a good affinity to the NMDA receptor (N-methyl-D-asparate); acute/cronic neurodegenerative diseases; bacterial/viral infections; antidepressants; analgesics
12/14/2004	US6831085 Methods and compositions utilizing quinazolinones
12/14/2004	US6831084 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity
12/14/2004	US6831083 Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof
12/14/2004	US6831082 Method of using soluble epoxide hydrolase inhibitors
12/14/2004	US6831080 Cinnamide derivatives as KCNQ potassium channel modulators
12/14/2004	US6831079 Vasopressin agonist formulation and process
12/14/2004	US6831078 3-aryl substituted having halo or alkylhalo groups; anxiety, epilepsy; presurgery muscle relaxant
12/14/2004	US6831077 Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
12/14/2004	US6831076 Epothilons C and D, preparation and compositions
12/14/2004	US6831075 Heterocyclic substituted pyrazolones
12/14/2004	US6831073 Treating postmenopausal estrogenic deficiencies without appearance of osteoporosis and/or withdrawal bleeding; continuously administering free or esterified estradiol and nomegestrol acetate
12/14/2004	US6831071 Oligonucleotide sequences for use as viricide or antitumor agents
12/14/2004	US6831069 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
12/14/2004	US6831057 Use of NF-κB inhibition in combination therapy for cancer
12/14/2004	US6830882 For antiobesity/diabetes agents; drug screening
12/14/2004	US6830765 Extract of green tea containing from 20% to 50% by mass of catechols expressed as epigallocatechol gallate
12/14/2004	US6830760 Glyburide composition
12/14/2004	US6830759 Antidiabetic preparation for oral administration
12/14/2004	US6830758 Patch containing drug; flexible backing; pressure sensitive adhesive
12/14/2004	US6830754 Amphipatic lipid containing a hydroxy and amide group; and of a surfactant in an aqueous medium; a washing-away type cosmetic composition comprising the dispersion
12/14/2004	US6830745 Compositions for treating biofilm
12/14/2004	US6830743 In Vivo stain compounds and methods of use to identify dysplastic tissue
12/14/2004	US6830692 Amino acid composition for hemodialysis
12/14/2004	CA2296535C Antisense oligonucleotide inhibition of ras
12/14/2004	CA2261597C Synthetic polysaccharides, preparation method therefor and pharmaceutical compositions containing same
12/14/2004	CA2235038C Use of a tnf alpha antagonist for treating neurogenic skin redness
12/14/2004	CA2225453C Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis
12/14/2004	CA2180867C Monomeric diols and phosphate linked oligomers formed therefrom
12/14/2004	CA2146320C Antisense oligonucleotide inhibition of the ras gene
12/14/2004	CA2136075C Heterocyclic ether compounds that enhance cognitive function
12/13/2004	CA2470263A1 New benzothiazine and benzothidiazine derivatives, their process of production and pharmaceutical compositions contained therein
12/13/2004	CA2470065A1 New derivatives of benzothiazine and benzothidiazine, preparation process thereof, and the pharmaceutical compounds containing them
12/13/2004	CA2467768A1 Stimulation of the synthesis and of the activity of an isoform of lysyl oxidase-like loxl for stimulating the formation of elastic fibres
12/13/2004	CA2432358A1 Nutritional supplementation for treating deficiency states in bowel disease
12/12/2004	CA2465693A1 Pharmaceutical compositions of atorvastatin
12/12/2004	CA2465621A1 Pharmaceutical compositions of atorvastatin
12/12/2004	CA2465565A1 Pharmaceutical compositions of atorvastatin
12/11/2004	CA2431560A1 Derivatives of streptogramins, their preparation and compositions containing them
12/09/2004	WO2004106519A2 Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids
12/09/2004	WO2004106511A1 OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND MEDICINAL COMPOSITION CONTAINING THE SAME
12/09/2004	WO2004106494A2 A preservative and method for preserving cells
12/09/2004	WO2004106493A2 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
12/09/2004	WO2004106492A2 Bicyclicpyrimidones and their use to treat diseases
12/09/2004	WO2004106486A2 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
12/09/2004	WO2004106378A2 Method of treating corneal transplant rejection by using vegf antagonists
12/09/2004	WO2004106358A1 Target-oriented chemotherapy for treating tumors of the sexual organs
12/09/2004	WO2004106355A1 Addition salts of azithromycin and citric acid and process for preparing them
12/09/2004	WO2004106354A1 Q-alkyl macrolide and azalide derivatives and regioselective process for their preparation
12/09/2004	WO2004106346A1 Indole derivatives with an improved antipsychotic activity
12/09/2004	WO2004106338A1 Novel crystalline forms of valacyclovir hydrochloride
12/09/2004	WO2004106333A1 Azabicycloalkane compounds as muscarinic receptor antagonists
12/09/2004	WO2004106325A1 Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
12/09/2004	WO2004106323A1 Method for producing cyclic diamine derivative or salt thereof
12/09/2004	WO2004106322A2 Polymorphs of aripiprazole
12/09/2004	WO2004106321A1 4-aryl-5h-thiophene-2-one derivatives and its preparation and use
12/09/2004	WO2004106319A1 Crystal forms of 4-[4-(4-fluorophenoxy)benzenesulfonylamino]-tetrahydropyran-4-carboxylic acid hydroxyamide
12/09/2004	WO2004106318A1 The extract method of cis-ligustilide and the pharmaceutical use of the same
12/09/2004	WO2004106317A1 Benzofuran compound and medicinal composition containing the same
12/09/2004	WO2004106310A1 Novel 3-substituted-1,4-benzodiazepines
12/09/2004	WO2004106307A2 Novel imidazole derivatives, the production thereof, and the use of the same as a medicament
12/09/2004	WO2004106305A1 New p2x7 receptor antagonists and their use
12/09/2004	WO2004106302A1 Novel substituted 3-sulfur indoles
12/09/2004	WO2004106300A1 Captopril derivatives
12/09/2004	WO2004106299A2 Substituted pyrrole derivatives and their use as hmg-co inhibitors
12/09/2004	WO2004106298A1 Indole derivatives with an improved antipsychotic activity
12/09/2004	WO2004106297A2 Nonionic surfactant compositions
12/09/2004	WO2004106296A2 Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
12/09/2004	WO2004106295A2 Substituted piperodines and pyrrolidines as calcium sensing receptor modulators and method
12/09/2004	WO2004106293A2 Oxazolyl - and thiazolyl - purine based tricyclic compounds.
12/09/2004	WO2004106292A1 Haloethyl urea compounds and their use to attenuate, inhibit or prevent non-cancerous pathogenic cellular proliferation and diseases associated therewith
12/09/2004	WO2004106291A1 Haloethyl urea compounds and the use thereof to attenuate, inhibit or prevent cancer cell migration
12/09/2004	WO2004106279A2 CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST
12/09/2004	WO2004105860A2 Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers
12/09/2004	WO2004105837A2 Compounds and methods for improving platelet recovery and function
12/09/2004	WO2004105824A1 A bioabsorbable delivery system
12/09/2004	WO2004105798A1 A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α
12/09/2004	WO2004105797A1 A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
12/09/2004	WO2004105796A1 A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
12/09/2004	WO2004105794A2 Continuous dosing regimen with abt-751
12/09/2004	WO2004105786A1 Adiponectin for treating cardiac disease
12/09/2004	WO2004105784A1 Class iii slrp agonists for the reduction of blood vessel formation
12/09/2004	WO2004105782A2 Drug delivery systems for tumor targeting ngr-molecules and uses thereof
12/09/2004	WO2004105778A1 Combination consisting of a magnesium preparation having a prolonged release and of another active substance, and use thereof in the fields of cosmetics, therapeutics and/or nutrition
12/09/2004	WO2004105777A1 Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases
12/09/2004	WO2004105776A1 Medicament for internal application, in particular against cancerous diseases
12/09/2004	WO2004105775A1 Pharmaceutical composition comprising glucan derived from microalgae

1 ... 4861 4862 4863 4864 4865 4866 4867 4868 4869 4870 4871 4872 4873 4874 4875 4876 4877 4878 4879 4880 4881 ... 7860